| 货号 | 3878T |
| 反应种属 | Human/Mouse/Rat/Monkey |
| 来源宿主 | Rabbit |
| 应用 | W |
| 目标/特异性 | Phospho-Vimentin (Ser82) Antibody detects endogenous levels of vimentin only when phosphorylated at Ser82. |
| 使用方法 | WB(1:1000) |
| 供应商 | CST |
| 灵敏度 | Endogenous |
| 背景 | The cytoskeleton consists of three types of cytosolic fibers: microfilaments (actin filaments), intermediate filaments, and microtubules. Major types of intermediate filaments are distinguished by their cell specific expression: cytokeratins (epithelial cells), glial fibrillary acidic protein (GFAP) (glial cells), desmin (skeletal, visceral, and certain vascular smooth muscle cells), vimentin (mesenchyme origin), and neurofilaments (neurons). GFAP and vimentin form intermediate filaments in astroglial cells and modulate their motility and shape (1). In particular, vimentin filaments are present at early developmental stages, while GFAP filaments are characteristic of differentiated and mature brain astrocytes. Thus, GFAP is commonly used as a marker for intracranial and intraspinal tumors arising from astrocytes (2). Vimentin is present in sarcomas, but not carcinomas, and its expression is examined in conjunction with that of other markers to distinguish between the two (3). Vimentins dynamic structural changes and spatial re-organization in response to extracellular stimuli help to coordinate various signaling pathways (4). Phosphorylation of vimentin at Ser56 in smooth muscle cells regulates the structural arrangement of vimentin filaments in response to serotonin (5,6). Remodeling of vimentin and other intermediate filaments is important during lymphocyte adhesion and migration through the endothelium (7). |
| 存放说明 | -20C |
| 计算分子量 | 57 |
| 参考文献 | 1 . Eng, L.F. et al. (2000) Neurochem Res 25, 1439-51. 2 . Goebel, H.H. et al. (1987) Acta Histochem Suppl 34, 81-93. 3 . Leader, M. et al. (1987) Histopathology 11, 63-72. 4 . Helfand, B.T. et al. (2004) J Cell Sci 117, 133-41. 5 . Tang, D.D. et al. (2005) Biochem J 388, 773-83. 6 . Fomina, I.G. et al. (1990) Klin Med (Mosk) 68, 125-7. 7 . Nieminen, M. et al. (2006) Nat Cell Biol 8, 156-62. 8 . Yamaguchi, T. et al. (2005) J Cell Biol 171, 431-6. 9 . Oguri, T. et al. (2006) Genes Cells 11, 531-40. 10 . Zhu, Q.S. et al. (2011) Oncogene 30, 457-70. 11 . Xue, G. and Hemmings, B.A. (2013) J Natl Cancer Inst 105, 393-404. 12 . Yamaguchi, T. et al. (2005) J Cell Biol 171, 431-6. 13 . Oguri, T. et al. (2006) Genes Cells 11, 531-40. |
Western blot analysis of extracts from HeLa cells, untreated or phosphorylated in vitro by PLK, using Phospho-Vimentin (Ser82) Antibody (upper). β-Actin Antibody #4976 (lower) was used as a loading control. 使用Phospho-Vimentin (Ser82) Antibody (上图)，免疫印迹（Western Blot）分析HeLa细胞中Phospho-Vimentin (Ser82)蛋白水平，细胞分为未处理和PLK激酶体外刺激。β-Actin Antibody #4967被使用作为内参照(下图)。 |
